Aristides Capital’s Humacyte HUMA Stock Holding History

Aristides Capital’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-162,900	Closed	-$156K	–	223
2025 Q4	$156K	Buy	+162,900	New	+$231K	0.03%	232

Other funds holding HUMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Aristides Capital's HUMA Position: Q1 2026 in Review

Aristides Capital sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 162,900 shares — an estimated $156K sold.

Aristides Capital first reported a position in HUMA in Q4 2025 and held it in 1 quarter. The position peaked at $156K in Q4 2025. 159 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

Aristides Capital reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
Aristides Capital sold 162,900 Humacyte shares in Q1 2026, an estimated $156K.
Aristides Capital first reported a position in Humacyte in Q4 2025 and held it in 1 quarter.
Aristides Capital's Humacyte position peaked at $156K in Q4 2025.
159 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Aristides Capital's 13F filing for Q1 2026, filed 14 May 2026.